Table 1.
Association between clinical characteristics and the epidermal growth factor receptor mutation status in patients with lung adenocarcinoma.
| Characteristic | Wild-type | Mutant-type | P-value |
|---|---|---|---|
| Age, mean ± SD, years | 63.61 ± 11.42 | 59.39 ± 9.73 | 0.005 |
| Gender, No. (%) | 0.001 | ||
| Male | 58 (68.2) | 50 (43.5) | |
| Female | 27 (31.8) | 65 (56.5) | |
| Family history, No. (%) | 0.870 | ||
| No | 81 (95.3) | 109 (94.8) | |
| Yes | 4 (4.7) | 6 (5.2) | |
| Smoking status, No. (%) | <0.001 | ||
| Never | 43 (50.6) | 89 (77.4) | |
| Ever | 42 (49.4) | 26 (22.6) | |
| Histologic grade, No. (%) | 0.015 | ||
| Poorly differentiated | 27 (41.5) | 20 (27.8) | |
| Moderately differentiated | 33 (50.8) | 36 (50.0) | |
| Well-differentiated | 5 (7.7) | 16 (22.2) | |
| Lymph node metastasis, No. (%) | 0.422 | ||
| No | 26 (30.6) | 29 (25.4) | |
| Yes | 59 (69.4) | 85 (74.6) | |
| Distant metastasis, No. (%) | 0.160 | ||
| No | 30 (35.3) | 30 (26.1) | |
| Yes | 55 (64.7) | 85 (73.9) | |
| Stage, No. (%) | 0.093 | ||
| I/II | 15 (17.6) | 11 (9.6) | |
| III/IV | 70 (82.4) | 104 (90.4) | |
| TTF-1, No. (%) | 0.021 | ||
| – | 9 (15.8) | 4 (4.5) | |
| + | 48 (84.2) | 84 (95.5) | |
| Ki-67, median [P25–P75] | 30 [20~50] | 30 [10~40] | 0.178 |
| CEA, median [P25–P75] | 4.70 [2.95~27.25] | 11.80 [2.40~61.90] | 0.270 |
| Diameter, median [P25–P75], mm | 34.00 [23.00~48.00] | 33.00 [23.00~46.00] | 0.396 |
| Site, No. (%) | 0.036 | ||
| Right upper lobe | 19 (22.4) | 38 (33.3) | |
| Right middle lobe | 3 (3.5) | 8 (7.0) | |
| Right lower lobe | 15 (17.6) | 23 (20.2) | |
| Left upper lobe | 19 (22.4) | 27 (23.7) | |
| Left lower lobe | 29 (34.1) | 18 (15.8) |
TTF-1, thyroid transcription factor- 1; CEA, carcinoembryonic antigen.